Estelle ESPINOS-PARROU

Prof. Estelle ESPINOS-PARROU


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2003 in Blood
Verified
Journal Article
Closed access
PDF file
RGRandy D. Gascoyne
Randy D. Gascoyne
LLLaurence Lamant
Laurence Lamant
JMJose I. Martin-Subero
Jose I. Martin-Subero
VLValia S. Lestou
Valia S. Lestou
NHNancy Lee Harris
Nancy Lee Harris
GDGeorges Delsol
Georges Delsol
Expression of ALK protein by lymphoid cells and the description of variant anaplastic lymphoma kinase (ALK) translocations have typically been restricted to cases of T-cell and null anaplastic large-cell lymphoma (ALCL). All such cases result from a novel fusion created by the ALK gene on chromosome 2p23 and NPM on 5q35 or other variant translocation partners. A rare variant of diffuse large B-cell lymphoma (DLBCL), originally described in 1997, was thought to overexpress full-length ALK in contrast to a chimeric protein characteristic of ALCL. However, full-length ALK protein lacks tyrosine kinase activity and thus the mechanism of oncogenesis has remained elusive. We describe 6 cases of ALK+ DLBCL characterized by a simple or complex t(2;17)(p23;q23) involving the clathrin gene (CLTC) at chromosome band 17q23 and the ALK gene at chromosome band 2p23. All cases were studied using fluorescence in situ hybridization (FISH), complemented in one case with standard cytogenetic analysis, multicolor karyotyping (M-FISH), and reverse transcriptase-polymerase chain reaction. These results clearly demonstrate that most cases of ALK+ DLBCL share the same mechanism of deregulated ALK expression. Moreover, these results demonstrate the presence of CLTC-ALK fusions in these tumors and extend the list of diseases associated with this genetic abnormality to include classical T-cell or null ALCL, ALK+ DLBCL, and inflammatory myofibroblastic tumors. (Blood. 2003;102:2568-2573)

20 June 2000 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PBPhilippe Bijlenga
Philippe Bijlenga
JLJian-Hui Liu
Jian-Hui Liu
EEEstelle ESPINOS-PARROU
Estelle ESPINOS-PARROU
CHCharles-Antoine Haenggeli
Charles-Antoine Haenggeli
JFJacqueline Fischer-Lougheed
Jacqueline Fischer-Lougheed
LBLaurent Bernheim
Laurent Bernheim
Mechanisms underlying Ca 2+ signaling during human myoblast terminal differentiation were studied using cell cultures. We found that T-type Ca 2+ channels (T-channels) are expressed in myoblasts just before fusion. Their inhibition by amiloride or Ni 2+ suppresses fusion and prevents an intracellular Ca 2+ concentration increase normally observed at the onset of fusion. The use of antisense oligonucleotides indicates that the functional T-channels are formed by α1H subunits. At hyperpolarized potentials, these channels allow a window current sufficient to increase [Ca 2+ ] i . As hyperpolarization is a prerequisite to myoblast fusion, we conclude that the Ca 2+ signal required for fusion is produced when the resting potential enters the T-channel window. A similar mechanism could operate in other cell types of which differentiation implicates membrane hyperpolarization.

31 October 2006 in Blood
Verified
Journal Article
Closed access
PDF file
LLLaurence Lamant
Laurence Lamant
ARAurélien de Reyniès
Aurélien de Reyniès
MDMarie-Michèle Duplantier
Marie-Michèle Duplantier
DRDavid S. Rickman
David S. Rickman
FSFrédérique Sabourdy
Frédérique Sabourdy
GDGeorges Delsol
Georges Delsol
With the use of microarray gene-expression profiling, we analyzed a homogeneous series of 32 patients with systemic anaplastic large-cell lymphoma (ALCL) and 5 ALCL cell lines. Unsupervised analysis classified ALCL in 2 clusters, corresponding essentially to morphologic subgroups (ie, common type vs small cell and “mixed” variants) and clinical variables. Patients with a morphologic variant of ALCL had advanced-stage disease. This group included a significant number of patients who experienced early relapse. Supervised analysis showed that ALK+ALCL and ALK− ALCL have different gene-expression profiles, further confirming that they are different entities. Among the most significantly differentially expressed genes between ALK+ and ALK− samples, we found BCL6, PTPN12, CEBPB, and SERPINA1 genes to be overexpressed in ALK+ ALCL. This result was confirmed at the protein level for BCL-6, C/EBPβ and serpinA1 through tissue microarrays. The molecular signature of ALK− ALCL included overexpression of CCR7, CNTFR, IL22, and IL21 genes but did not provide any obvious clues to the molecular mechanism underlying this tumor subtype. Once confirmed on a larger number of patients, the results of the present study could be used for clinical and therapeutic management of patients at the time of diagnosis.

20 May 2003 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
LLLaurence Lamant
Laurence Lamant
RGRandy D. Gascoyne
Randy D. Gascoyne
MDMarie Michèle Duplantier
Marie Michèle Duplantier
FAFlorence Armstrong
Florence Armstrong
ARAshraf Raghab
Ashraf Raghab
EEEstelle ESPINOS-PARROU
Estelle ESPINOS-PARROU

1 December 2004 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
Karen PulfordKaren Pulford
Karen Pulford
LLL. Lamant
L. Lamant
EEEstelle ESPINOS-PARROU
Estelle ESPINOS-PARROU
QJQ. Jiang
Q. Jiang
LXL. Xue
L. Xue
SMS. W. Morris
S. W. Morris

21 June 2004 in Oncogene
Verified
Journal Article
Closed access
FAFlorence Armstrong
Florence Armstrong
MDMarie-Michèle Duplantier
Marie-Michèle Duplantier
PTPascal Trempat
Pascal Trempat
CHCorinne Hieblot
Corinne Hieblot
LLLaurence Lamant
Laurence Lamant
CTChristian TOURIOL
Christian TOURIOL